Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
The Lancet. Oncology.
Times cited: 15
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Times cited: 11
- Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International journal of cancer. 2015 Academic Article GET IT
Evolutionary dynamics of cancer in response to targeted combination therapy.
Times cited: 160